Monopar Announces Radiopharma Presentation Selected for Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting
April 18 2024 - 8:00AM
Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage
biopharmaceutical company focused on developing innovative
treatments for cancer patients, today announced that its abstract
on the preclinical data for its radiopharmaceutical program
MNPR-101-Zr (MNPR-101 conjugated to zirconium-89) submitted to the
Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2024
Annual Meeting has been selected for a presentation. SNMMI 2024,
held in Toronto, Canada, is recognized as the premier educational,
scientific, and research event in the radiopharma space.
Meeting Details:
Event: Society of Nuclear Medicine and Molecular
Imaging (SNMMI) 2024 Annual Meeting
Date: June 8 – June 11, 2024
Location: Metro Toronto Convention Centre, Toronto,
ON, Canada
About Monopar Therapeutics Inc.
Monopar Therapeutics is a clinical-stage
biopharmaceutical company focused on developing innovative
treatments for cancer patients. Monopar's pipeline consists of
Phase 1-stage MNPR-101 for radiopharmaceutical use in various
advanced cancers; Phase 1b-stage camsirubicin for the treatment of
advanced soft tissue sarcoma; and an early-stage camsirubicin
analog, MNPR-202. For more information, visit: www.monopartx.com
and ir.monopartx.com/presentations.
CONTACT:
Monopar Therapeutics Inc.Investor
RelationsKim R. TsuchimotoChief Financial
Officerkimtsu@monopartx.com
Follow Monopar on social media for updates:
Twitter: @MonoparTx LinkedIn: Monopar
Therapeutics
Monopar Therapeutics (NASDAQ:MNPR)
Historical Stock Chart
From Apr 2024 to May 2024
Monopar Therapeutics (NASDAQ:MNPR)
Historical Stock Chart
From May 2023 to May 2024